CLS studies demonstrate safe treatment with the TRANBERG system
Clinical Laserthermia Systems (CLS) (publ), which develops and markets Interstitial Laser Thermo Therapy imILT, a polyclinical, heat-induced cancer immunotherapy, has completed the first phase of a clinical study to evaluate the safety of the TRANBERG system with respect to imILT treatment. A total of eight treatments have been included in this first internal Post-Market Clinical Follow-up report, from which it can be concluded that the imILT treatment is safe, provided that the procedures are performed in accordance with the treatment instructions. No serious side effects that can be linked to the treatment have been reported. Post-Market Clinical Follow-up is performed for all CE-marked products and is carried out continuously for the entire duration that the product is on the market.
"The first Post-Market Follow-up report is now available. "The report is based on eight treatments and no serious side effects have been observed," says CLS CEO Lars-Erik Eriksson. "When it comes to ease of handling, or in other word how easy our product is to use for the treating physician, we have received some feedback that has resulted in us introducing certain minor alterations. These will be evaluated in continued studies. Collaboration with the medical teams at the clinics has worked very well," Lars-Erik Eriksson states.
The treatments have been carried out on the following cancer types, all of which have involved the treatment of metastases: skin cancer, pancreatic cancer, breast cancer and bowel cancer. The treatments have been carried out at four different hospitals.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Aktietorget under the stock symbol CLS B. More information is available on the Company's website www.clinicallaser.se